Pluristem Therapeutics Inc. (PSTI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on July 19, 2021, regarding events occurring on July 15, 2021. The company is incorporated in Nevada and its common stock trades on The Nasdaq Global Market under the symbol PSTI.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of two new members to the Board of Directors, effective immediately on July 15, 2021:
- Prof. Varda Shalev: Appointed as a director. She is a professor at Tel Aviv University, CMO of Alike, and has extensive experience in medical informatics and healthcare management.
- Mr. Doron Birger: Appointed as a director. He holds multiple board positions in the medical technology sector, including Sight Diagnostic Ltd., Nurami Medical Ltd., and IceCure Medical Ltd.
Both directors will serve until the next general meeting of shareholders. Their compensation will align with the fees paid to other non-executive directors as outlined in the 2020 Form 10-K.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, or specific risk factors. The report confirms there are no family relationships between the new directors and existing officers, and no reportable related party transactions under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of the new board appointments (July 15, 2021).
- Confirm the compensation structure for the new directors matches existing non-executive director fees.
- Review the 2020 Form 10-K for details on the standard director fee schedule.
- Note that committee assignments for the new directors have not yet been determined.